Clinical trials: Covid19- Coronavirus- Sars-cov-2
Long COVID, Post COVID-19 Condition
Effect of Hi-OxSR for the Treatment of Post COVID Condition
The RECLAIM study platform will be used to explore whether the use of the Hi-OxSR device improves the symptoms of post covid cognitive dysfunction.
- Conditions
- Long COVID, Post COVID-19 Condition, Post Acute Sequelae of COVID-19
- Trial name
- RECLAIM-HiOxSR (NCT06928506)
- Testing
- Hi-OxSR device, Hi-Ox device
- Where
- 3 sites in Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI (NCT04346199)
- Testing
- Acalabrutinib
- Where
- 50 sites in Argentina, Brazil and 12 more
- Volunteers
- 177 people
- Sponsor
- AstraZeneca
SARS-CoV-2 Serological Status, SARS-CoV-2 Seroprevalence
Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)
COVID-19 is a new emerging disease caused by infection with the SARS-CoV-2 coronavirus, with no specific therapeutic options. Since the end of February 2020, the Strasbourg University Hospital (HUS) had faced a sudden increase of…
- Trial name
- SeroCoV-HUS (NCT04441684)
- Testing
- Blood sample for serological test
- Where
- France
- Volunteers
- 1,466 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Postural Orthostatic Tachycardia Syndrome, Post Acute Sequelae of SARS CoV 2 Infection
NC Testing in LC & POTS
Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction.
- Trial name
- NCT05914649
- Testing
- IV normal saline (999 mL infusion), IV normal saline (50 mL infusion)
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Calgary
COVID-19
Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)
The 2019 Coronavirus disease outbreak (COVID-19) was first reported at the end of 2019 in Wuhan China as a severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection.
- Trial name
- NCT05172193
- Testing
- SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated
- Where
- 7 sites in Indonesia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PT. Kimia Farma (Persero) Tbk
SARS-CoV-2 Infection
Mucosal Immunity Against SARS-CoV-2 Infection in COVID-19 Patients
In this study nasal fluid (mucosal lining fluid), nose and throat swabs and blood was collected from patients with a confirmed SARS-CoV-2 infection who remained in home isolation, as well as from their household contacts who…
- Trial name
- MuCo (NCT04590352)
- Testing
- nasopharyngeal and throat swab, collection of mucosal lining fluid, blood collection via fingerprick
- Where
- Netherlands
- Volunteers
- 187 people
- Sponsor
- Radboud University Medical Center
Long COVID
A Practical RCT of TCM in the Treatment of LCOVID and Analysis of Syndrome Types and Medication Characteristics.
This is a multi-center, outcome assessor-blinded, practical randomized controlled trial, aiming to compare the actual clinical effectiveness of individualized traditional Chinese medicine and conventional Western medicine in the…
- Trial name
- NCT06095258
- Testing
- Traditional Chinese medicine treatment, Western medicine treatment
- Volunteers
- 162 people
- Sponsor
- Chinese University of Hong Kong
Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
COVID-19 and Anti-CD14 Treatment Trial
This study aims to address the following objectives: 1. To determine the efficacy of IC14, an anti-CD14 chimeric monoclonal antibody, in patients hospitalized with respiratory disease and hypoxemia due to SARS-CoV-2, in terms of…
- Trial name
- CaTT (NCT04391309)
- Testing
- anti-CD14, remdesivir
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815…
- Trial name
- NextCOVE (NCT05815498)
- Testing
- mRNA-1283.222, mRNA-1273.222, mRNA-1283.815
- Where
- 230 sites in United States, Canada and 2 more
- Volunteers
- 13,553 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Coronavirus Disease 2019
Fostamatinib for Hospitalized Adults With COVID-19
Background: COVID-19 is a new disease caused by SARS-CoV-2 that was identified in 2019. Some people who get sick with COVID-19 become ill requiring hospitalization. There are some medicines that may help with recovery.
- Trial name
- NCT04579393
- Testing
- fostamatinib
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sars-CoV2, Serum; Disease
Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic
The question of the immune response of the population, particularly of professional populations in contact with vulnerable populations (such as those with chronic conditions such as cancer), is an important issue.
- Trial name
- PRO-SERO-COV (NCT04426006)
- Testing
- PRO-SERO-COV
- Where
- France
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- Institut Bergonié
SARS-CoV-2 Acute Respiratory Disease, SARS-CoV-2 Sepsis
The Corona Study of Middle Norway
CUT COVID is a cohort study establised to collect information on patients hospitalized because or with infection by SARS-CoV-2. The cohort data includes clinical data and biological samples from multiple timepoints during…
- Conditions
- SARS-CoV-2 Acute Respiratory Disease, SARS-CoV-2 Sepsis, SARS CoV 2 Infection
- Trial name
- CUT COVID-19 (NCT05638178)
- Testing
- No intervention
- Where
- 5 sites in Norway
- Volunteers
- 223 people
- Sponsor
- St. Olavs Hospital
Post-Acute COVID-19 Syndrome
Microbial and Cytokine Signatures in Long COVID Patients
We aim at identifying potential biomarkers in plasma indicative of post-acute coronavirus SARS-CoV-2 Syndrome (Long COVID). Our case-control study will compare Long COVID patients to healthy patients from Sutter Health.
- Trial name
- NCT07074158
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Palo Alto Medical Foundation
COVID 19
Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Study to Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
- Trial name
- NCT04561076
- Testing
- HLX70
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hengenix Biotech Inc
Covid19
Prevalence Of COVID-19 Among Health-workers in a French General Hospital
The aim of this study is to evaluate the prevalence of COVID-19 among the workers of our hospital and the factors that are likely to influence this prevalence.
- Trial name
- POCAH-COVID (NCT04548908)
- Testing
- Serelogy testing, RT PCR
- Where
- France
- Volunteers
- 1,300 people
- Sponsor
- Centre Hospitalier Sud Essonne
Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus)
Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster
This is a descriptive, open-label, multicenter, non-randomized, uncontrolled phase I clinical study to evaluate the safety, reactogenicity, and immunogenicity of the COVID-19 Vaccine (mRNA) - Bio-Manguinhos/Fiocruz at doses of 25…
- Trial name
- NCT07640308
- Testing
- Grupo 1 - dose 25 μg, Group 2 - 50 μg dose, Group 3 - 100 μg
- Volunteers
- 90 people
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Coronavirus, Covid19
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine (CVnCoV) at different dose levels and to evaluate the humoral immune response after 1…
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04515147
- Testing
- CVnCoV 6 μg, CVnCoV 12 μg, Hepatitis A vaccine
- Where
- 2 sites in Panama, Peru
- Volunteers
- 668 people, healthy volunteers welcome
- Sponsor
- CureVac
COVID-19, SARS-CoV-2 Infection
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.
The objective of this study is to evaluate the safety, tolerability, and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with inactivated COVID-19 vaccine.
- Trial name
- NCT05043285
- Testing
- SCTV01C
- Where
- United Arab Emirates
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
SARS-CoV 2, COVID19
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
The administration of Calcifediol in patients with COVID-19, will reduce the development of SARS and the worsening of the various phases of the syndrome.
- Conditions
- SARS-CoV 2, COVID19, SARS (Severe Acute Respiratory Syndrome), Cytokine Release Syndrome
- Trial name
- COVIDIOL (NCT04366908)
- Testing
- BAT + Calcifediol, BAT
- Where
- Spain
- Volunteers
- 517 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Covid19
Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
This is a 2-part, 2-arm, Phase 2 , multicentre, randomized, double-blind, placebo-controlled study in adults with COVID-19 with gastrointestinal infection.
- Trial name
- RESERVOIR (NCT04858425)
- Testing
- Niclosamide
- Where
- 25 sites in United States, India and 1 more
- Volunteers
- 166 people
- Sponsor
- Entero Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.